PIK3CD and hematologic disorder: Due to the high expression levels of p110δ and p110γ in leukocytes, the p110δ inhibitors CAL-101 and AMG319, as well as the p110δ/γ inhibitor INK1197 are currently in phase I/II clinical trials for patients with hematologic malignancies including leukemia, lymphoma and myeloma.